In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Y-mAbs goes public via $102.7mm IPO

Executive Summary

Cancer immunotherapies developer Y-mAbs Therapeutics Inc. completed its initial public offering. The company netted $102.7mm through the sale of 6.9mm common shares (including the overallotment) at $16. (It had originally planned to sell 5.33mm shares at $14-16.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies